Barclays’s BiomX PHGE Stock Holding History

Barclays’s Portfolio PHGE Stock Details PHGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.94K	Hold	1,316	–	–	﹤0.01%	4777
2025 Q4	$2.46K	Hold	1,316	–	–	﹤0.01%	5033
2025 Q3	$13.1K	Hold	1,316	–	–	﹤0.01%	4998
2025 Q2	$11.3K	Hold	1,316	–	–	﹤0.01%	4906
2025 Q1	$13.9K	Hold	1,316	–	–	﹤0.01%	4833
2024 Q4	$18.3K	Hold	1,316	–	–	﹤0.01%	4928
2024 Q3	$25.5K	Hold	1,316	–	–	﹤0.01%	4866
2024 Q2	$84K	Buy	+1,316	New	+$88.7K	﹤0.01%	3990

Other funds holding PHGE

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Barclays's PHGE Position: Q1 2026 in Review

Barclays held its BiomX (PHGE) position steady in Q1 2026 at 1,316 shares worth $4.94K. The position accounts for ﹤0.01% of the portfolio, ranked #4777.

Barclays first reported a position in PHGE in Q2 2024 and has held it in 8 quarters since. The position peaked at $84K in Q2 2024. 13 funds tracked by Wall St. Rank hold PHGE as of Q1 2026.

Barclays held 1,316 shares of BiomX worth $4.94K as of Q1 2026.
Barclays left its BiomX share count unchanged in Q1 2026.
BiomX made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #4777 holding.
Barclays first reported a position in BiomX in Q2 2024 and has held it in 8 quarters since.
Barclays's BiomX position peaked at $84K in Q2 2024.
13 funds tracked by Wall St. Rank held BiomX as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.